StocksDiva Bio Bin

[PoemStone]

ADXS 04-05-2012 Advaxis Announces Collaboration with the Karolinska Institutet
http://finance.yahoo.com/news/advaxis-announces-collaboration-karolinska-institutet-132300285.html

PRINCETON, N.J.--(BUSINESS WIRE)--

Advaxis, Inc., (OTCBB: ADXS.OB - News), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced that it has entered into a research collaboration with Professor Marianne van Hage, research group leader and Head of the Clinical Immunology and Allergy Unit and Vice Head of the Department of Medicine at Karolinska Institutet in Stockholm, Sweden. The purpose of this collaboration is to evaluate the potential of Advaxis immunotherapies to treat and prevent allergies in established scientific models of allergic diseases.

Prof. Marianne van Hage’s research is focused on further understanding the molecular mechanisms of underlying allergic disease and the function of allergens, and to develop new diagnostic markers and new strategies for vaccination. Her work using cat allergy as a model system has resulted in significant insights and understanding to develop treatments and prevention options for allergic responses. Prof. van Hage will be using Advaxis immunotherapies to develop allergy treatments using the models she and her team have developed. If successful, this work may be applied to other allergic diseases.

“The Karolinska Institutet is a world-renowned group of researchers and we are pleased that our immunotherapies may help to better understand allergic responses and potentially provide additional prevention and treatment options,” said Advaxis Chairman/CEO Thomas A. Moore.

“We are very excited about the collaboration with Advaxis and hope to develop an efficient and safe vaccine for cat allergy, which could lead to other allergy treatments in the future,” commented Prof. Marianne van Hage.

About the Laboratory of Professor Marianne van Hage

Prof. Marianne van Hage is research group leader and Head of the Clinical Immunology and Allergy Unit and Vice Head of the Department of Medicine at Karolinska Institutet in Stockholm, Sweden. Her research is in front line and performed in an integrated basic and clinical scientific environment with successful collaboration with well-established national and international groups in the field of molecular biology, cell biology, biochemistry, immunohistochemistry, epidemiology, and genetics. Her investigations are primarily oriented towards elucidation of molecular mechanisms of allergic inflammation, to new diagnostic and therapeutic strategies for allergic disease, and covers basic as well as clinical allergy research.

About Advaxis, Inc.

Advaxis is a clinical-stage biotechnology company developing the next generation of immunotherapies for cancer and infectious diseases. Advaxis immunotherapies are based on a novel platform technology using live, attenuated bacteria that are bio-engineered to secrete an antigen/adjuvant fusion protein that is designed to redirect the powerful immune response all human beings have to the bacterium to the cancer itself.

Advaxis’ lead construct, ADXS-HPV, is being evaluated in 4 Phase 2 clinical trials that are open for enrollment for HPV-associated diseases: CIN 2/3 (US study, Clinical Trials.gov Identifier NCT01116245), locally advanced cervical cancer (GOG/NCI US study, Clinical Trials.gov Identifier NCT01266460), recurrent/refractory cervical cancer (India), and head & neck cancer (CRUK study). Over fifteen (15) distinct constructs are in various stages of development, developed directly by the Company and through strategic collaborations with recognized centers of excellence such as: the National Cancer Institute, Cancer Research – UK, the Wistar Institute, the University of Pennsylvania, the University of British Columbia, the Karolinska Institutet, and others. For more information please visit: advaxis.com | Facebook | twitter | LinkedIn